Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma

2017 ◽  
Vol 13 (5s) ◽  
pp. 3-6 ◽  
Author(s):  
Concetta Conticello ◽  
Marina Parisi ◽  
Alessandra Romano ◽  
Valeria Calafiore ◽  
Flavia Ancora ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Therapeutic Approach ◽  
Immunomodulatory Drugs ◽  
Refractory Multiple Myeloma

scholarly journals Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Muhammad Husnain ◽  
Sandra Kurtin ◽  
Nikki Barkett ◽  
Irbaz Bin Riaz ◽  
Amit Agarwal
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Median Overall Survival ◽  
Overall Response Rate ◽  
Response Rate ◽  
Human Monoclonal Antibody ◽  
Proteasome Inhibitors ◽  
Recent Analysis ◽  
Immunomodulatory Drugs ◽  
Refractory Multiple Myeloma

Patients with relapsed and refractory multiple myeloma have poor prognosis. A recent analysis of patients with relapsed and refractory multiple myeloma who were refractory to both proteasome inhibitors and immunomodulatory drugs showed the median overall survival of 9 months only. Daratumumab is the first-in-class human monoclonal antibody against CD38 cells which was studied in phase I/II trials for treatment of these patients with relapsed refractory multiple myeloma. It showed an overall response rate of 36% and a median overall survival (OS) of 17 months in these patients. We report a case of 40-year-old man with immunoglobulin D (IgD) multiple myeloma whose disease was refractory to at least 5 different chemotherapy regimens including proteasome inhibitors and immunomodulatory drugs. The clinical studies assessing daratumumab did not include any patients with IgD myeloma which is a rare form of multiple myeloma and to our knowledge is the first study reporting use of daratumumab in IgD myeloma.

scholarly journals Management of Relapsed and Relapsed/Refractory Multiple Myeloma

2011 ◽  
Vol 9 (10) ◽  
pp. 1209-1216 ◽  
Author(s):  
Jacob P. Laubach ◽  
Constantine S. Mitsiades ◽  
Anuj Mahindra ◽  
Marlise R. Luskin ◽  
Jacalyn Rosenblatt ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Proteasome Inhibitor ◽  
Treatment Options ◽  
Immunomodulatory Drugs ◽  
Significant Progress ◽  
Refractory Multiple Myeloma ◽  
The Past ◽  
Drug Classes ◽  
Almost All ◽  
Over Time

Despite significant progress in the treatment of multiple myeloma (MM) over the past decade, this disease remains incurable and almost all patients ultimately experience relapse and become refractory to treatment over time. However, the outlook for patients with relapsed MM has improved markedly with the use of the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. Moreover, the development of new drug classes based on preclinical rationale and the introduction of next-generation agents is likely to further expand treatment options and improve outcomes for relapsed MM.

Unstable Plasma Thalidomide Concentration in Patients with Refractory Multiple Myeloma

2004 ◽  
Vol 10 (3) ◽  
pp. 132-136 ◽  
Author(s):  
TOMOKO KODAMA ◽  
RYUYA HORIUCHI ◽  
NORIFUMI TSUKAMOTO ◽  
YOSHIHISA NOJIMA ◽  
HIROKAZU MURAKAMI
Keyword(s):  
Multiple Myeloma ◽  
Refractory Multiple Myeloma ◽  
Unstable Plasma
Sign in / Sign up

Export Citation Format

Share Document